Top

Gepubliceerd in:

07-04-2020

Parental health spillover effects of paediatric rare genetic conditions

Auteurs: You Wu, Hareth Al-Janabi, Andrew Mallett, Catherine Quinlan, Ingrid E. Scheffer, Katherine B. Howell, John Christodoulou, Richard J. Leventer, Paul J. Lockhart, Zornitza Stark, Tiffany Boughtwood, Ilias Goranitis

Gepubliceerd in: Quality of Life Research | Uitgave 9/2020

Abstract

Purpose

The complexity and severity of rare genetic conditions pose substantial burden to families. While the importance of spillovers on carers’ health in resource allocation decisions is increasingly recognised, there is significant lack of empirical evidence in the context of rare diseases. The objective of this study was to estimate the health spillovers of paediatric rare genetic conditions on parents.

Methods

Health-related quality-of-life (HRQoL) data from children with rare genetic conditions (genetic kidney diseases, mitochondrial diseases, epileptic encephalopathies, brain malformations) and their parents were collected using the CHU9D and SF-12 measures, respectively. We used two approaches to estimate parental health spillovers. To quantify the ‘absolute health spillover’, we matched our parent cohort to the Australian general population. To quantify the ‘relative health spillover’, regression models were applied using the cohort data.

Results

Parents of affected children had significantly lower HRQoL compared to matched parents in the general public (− 0.06; 95% CIs − 0.08, − 0.04). Multivariable regression demonstrated a positive association between parental and child health. The mean magnitude of HRQoL loss in parents was estimated to be 33% of the HRQoL loss observed in children (95% CIs 21%, 46%).

Conclusion

Paediatric rare genetic conditions appear to be associated with substantial parental health spillovers. This highlights the importance of including health effects on family members and caregivers into economic evaluation of genomic technologies and personalised medicine. Overlooking spillover effects may undervalue the benefits of diagnosis and management in this context. This study also expands the knowledge of family spillover to the rare disease spectrum.

vorige artikel Developmental differences in health-related quality of life in adolescent and young adult cancer survivors

volgende artikel The association of socio-economic status, dental anxiety, and behavioral and clinical variables with adolescents’ oral health-related quality of life

Alleen toegankelijk voor geautoriseerde gebruikers

Boycott, K. M., Vanstone, M. R., Bulman, D. E., & MacKenzie, A. E. (2013). Rare-disease genetics in the era of next-generation sequencing: Discovery to translation. Nature Reviews Genetics, 14(10), 681.PubMedCrossRef

Stark, Z., Schofield, D., Martyn, M., Rynehart, L., Shrestha, R., Alam, K., et al. (2019). Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. Genetics in Medicine, 21(1), 173–180. https://doi.org/10.1038/s41436-018-0006-8.PubMedCrossRef

Slade, A., Isa, F., Kyte, D., Pankhurst, T., Kerecuk, L., Ferguson, J., et al. (2018). Patient reported outcome measures in rare diseases: A narrative review. Orphanet Journal of Rare Diseases, 13(1), 61.PubMedPubMedCentralCrossRef

Wright, C. F., FitzPatrick, D. R., & Firth, H. V. (2018). Paediatric genomics: Diagnosing rare disease in children. Nature Reviews Genetics, 19(5), 253.PubMedCrossRef

Madeo, A. C., O'Brien, K. E., Bernhardt, B. A., & Biesecker, B. B. (2012). Factors associated with perceived uncertainty among parents of children with undiagnosed medical conditions. American Journal of Medical Genetics Part A, 158A(8), 1877–1884. https://doi.org/10.1002/ajmg.a.35425.PubMedPubMedCentralCrossRef

Zurynski, Y., Deverell, M., Dalkeith, T., Johnson, S., Christodoulou, J., Leonard, H., et al. (2017). Australian children living with rare diseases: Experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet Journal of Rare Diseases, 12(1), 68.PubMedPubMedCentralCrossRef

Pelentsov, L. J., Fielder, A. L., Laws, T. A., & Esterman, A. J. (2016). The supportive care needs of parents with a child with a rare disease: Results of an online survey. BMC Family Practice, 17(1), 88.PubMedPubMedCentralCrossRef

Pelentsov, L. J., Laws, T. A., & Esterman, A. J. (2015). The supportive care needs of parents caring for a child with a rare disease: A scoping review. Disability and Health Journal, 8(4), 475–491.PubMedCrossRef

Wittenberg, E., James, L. P., & Prosser, L. A. (2019). Spillover effects on caregivers’ and family members’ utility: A systematic review of the literature. PharmacoEconomics, 37(4), 475–499.PubMedCrossRef

10.

Wittenberg, E., & Prosser, L. A. (2016). Health as a family affair. New England Journal of Medicine, 374(19), 1804–1806.PubMedCrossRef

11.

National Institue for Health and Care Excellence (2013). Guide to the methods of technology appraisal. https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 03 Jan 2019.

12.

Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., et al. (2016). Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine. JAMA, 316(10), 1093–1103.PubMedCrossRef

13.

Al-Janabi, H., McLoughlin, C., Oyebode, J., Efstathiou, N., & Calvert, M. (2019). Six mechanisms behind carer wellbeing effects: A qualitative study of healthcare delivery. Social Science & Medicine, 2, 112382.CrossRef

14.

Brouwer, W. B. (2019). The inclusion of spillover effects in economic evaluations: Not an optional extra. PharmacoEconomics, 37(4), 451–456.PubMedCrossRef

15.

Lavelle, T. A., D’Cruz, B. N., Mohit, B., Ungar, W. J., Prosser, L. A., Tsiplova, K., et al. (2019). Family spillover effects in pediatric cost-utility analyses. Applied Health Economics and Health Policy, 17(2), 163–174.PubMedCrossRef

16.

Stark, Z., Lunke, S., Brett, G. R., Tan, N. B., Stapleton, R., Kumble, S., et al. (2018). Meeting the challenges of implementing rapid genomic testing in acute pediatric care. Genetics in Medicine, 20(12), 1554–1563. https://doi.org/10.1038/gim.2018.37.PubMedCrossRef

17.

Howell, K. B., Eggers, S., Dalziel, K., Riseley, J., Mandelstam, S., Myers, C. T., et al. (2018). A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy. Epilepsia, 59(6), 1177–1187. https://doi.org/10.1111/epi.14087.PubMedPubMedCentralCrossRef

18.

Schwarze, K., Buchanan, J., Taylor, J. C., & Wordsworth, S. (2018). Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genetics in Medicine, 20(10), 1122.PubMedCrossRef

19.

Phillips, K. A., Deverka, P. A., Marshall, D. A., Wordsworth, S., Regier, D. A., Christensen, K. D., et al. (2018). Methodological issues in assessing the economic value of next-generation sequencing tests: Many challenges and not enough solutions. Value in Health, 21(9), 1033–1042.PubMedPubMedCentralCrossRef

20.

Stark, Z., Boughtwood, T., Phillips, P., Christodoulou, J., Hansen, D. P., Braithwaite, J., et al. (2019). Australian genomics: A federated model for integrating genomics into healthcare. The American Journal of Human Genetics, 105(1), 7–14.PubMedCrossRef

21.

Taylor, N., Best, S., Martyn, M., Long, J. C., North, K. N., Braithwaite, J., et al. (2019). A transformative translational change programme to introduce genomics into healthcare: A complexity and implementation science study protocol. British Medical Journal Open, 9(3), e024681. https://doi.org/10.1136/bmjopen-2018-024681.CrossRef

22.

Ware, J. E., Kosinski, M., Turner-Bowker, D. M., Gandek, B., QualityMetric, I., New England Medical Center, H., et al. (2002). How to score version 2 of the SF-12 health survey (with a supplement documenting version 1). Lincoln, R.I.; Boston, MA.: QualityMetric Inc. ; Health Assessment Lab.

23.

Brazier, J. E., & Roberts, J. (2004). The estimation of a preference-based measure of health from the SF-12. Medical Care, 3, 851–859.CrossRef

24.

Ratcliffe, J., Huynh, E., Chen, G., Stevens, K., Swait, J., Brazier, J., et al. (2016). Valuing the child health utility 9D: Using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm. Social Science & Medicine, 157, 48–59.CrossRef

25.

Stevens, K. (2012). Valuation of the child health utility 9D index. PharmacoEconomics, 30(8), 729–747.PubMedCrossRef

26.

Al-Janabi, H., Van Exel, J., Brouwer, W., Trotter, C., Glennie, L., Hannigan, L., et al. (2016). Measuring health spillovers for economic evaluation: A case study in meningitis. Health Economics, 25(12), 1529–1544.PubMedCrossRef

27.

Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292.PubMedCrossRef

28.

Faria, R., Gomes, M., Epstein, D., & White, I. R. (2014). A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics, 32(12), 1157–1170. https://doi.org/10.1007/s40273-014-0193-3.PubMedPubMedCentralCrossRef

29.

Simons, C. L., Rivero-Arias, O., Yu, L.-M., & Simon, J. (2015). Multiple imputation to deal with missing EQ-5D-3L data: Should we impute individual domains or the actual index? Quality of Life Research, 24(4), 805–815. https://doi.org/10.1007/s11136-014-0837-y.PubMedCrossRef

30.

Chen, G., Flynn, T., Stevens, K., Brazier, J., Huynh, E., Sawyer, M., et al. (2015). Assessing the health-related quality of life of Australian adolescents: an empirical comparison of the child health utility 9D and EQ-5D-Y instruments. Value in Health, 18(4), 432–438.PubMedCrossRef

31.

Kwon, J., Kim, S. W., Ungar, W. J., Tsiplova, K., Madan, J., & Petrou, S. (2018). A systematic review and meta-analysis of childhood health utilities. Medical Decision Making, 38(3), 277–305.PubMedCrossRef

32.

Prosser, L. A., & Wittenberg, E. (2019). Advances in methods and novel applications for measuring family spillover effects of illness. PharmacoEconomics, 37(4), 447–450. https://doi.org/10.1007/s40273-019-00794-5.PubMedCrossRef

33.

Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research, 14(6), 1523–1532.PubMedCrossRef

34.

Tilford, J. M., Grosse, S. D., Robbins, J. M., Pyne, J. M., Cleves, M. A., & Hobbs, C. A. (2005). Health state preference scores of children with spina bifida and their caregivers. Quality of Life Research, 14(4), 1087–1098.PubMedCrossRef

35.

Hoefman, R. J., van Exel, J., & Brouwer, W. (2013). How to include informal care in economic evaluations. PharmacoEconomics, 31(12), 1105–1119.PubMedCrossRef

36.

Al-Janabi, H., Van Exel, J., Brouwer, W., & Coast, J. (2016). A framework for including family health spillovers in economic evaluation. Medical Decision Making, 36(2), 176–186.PubMedPubMedCentralCrossRef

37.

Tubeuf, S., Saloniki, E.-C., & Cottrell, D. (2019). Parental health spillover in cost-effectiveness analysis: Evidence from self-harming adolescents in England. PharmacoEconomics, 37(4), 513–530. https://doi.org/10.1007/s40273-018-0722-6.PubMedCrossRef

38.

Brown, C. C., Tilford, J. M., Payakachat, N., Williams, D. K., Kuhlthau, K. A., Pyne, J. M., et al. (2019). Measuring health spillover effects in caregivers of children with autism spectrum disorder: A comparison of the EQ-5D-3L and SF-6D. PharmacoEconomics, 37(4), 609–620.PubMedPubMedCentralCrossRef

39.

Nan, L., Pei, W., Alex, Z. F., Jeffery, A. J., & Stephen Joel, C. (2012). Preference-based SF-6D scores derived from the SF-36 and SF-12 have different discriminative power in a population health survey. Medical Care, 50(7), 627. https://doi.org/10.1097/MLR.0b013e31824d7471.CrossRef

40.

Brouwer, W., Van Exel, N., Van Gorp, B., & Redekop, W. (2006). The CarerQol instrument: A new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. Quality of Life Research, 15(6), 1005–1021.PubMedCrossRef

41.

Al-Janabi, H., Coast, J., & Flynn, T. N. (2008). What do people value when they provide unpaid care for an older person? A meta-ethnography with interview follow-up. Social Science & Medicine, 67(1), 111–121.CrossRef

42.

Al-Janabi, H., Flynn, T. N., & Coast, J. (2012). Development of a self-report measure of capability wellbeing for adults: The ICECAP-A. Quality of Life Research, 21(1), 167–176.PubMedCrossRef

Titel: Parental health spillover effects of paediatric rare genetic conditions
Auteurs: You Wu
Hareth Al-Janabi
Andrew Mallett
Catherine Quinlan
Ingrid E. Scheffer
Katherine B. Howell
John Christodoulou
Richard J. Leventer
Paul J. Lockhart
Zornitza Stark
Tiffany Boughtwood
Ilias Goranitis
Publicatiedatum: 07-04-2020
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 9/2020
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-020-02497-3

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 9/2020

A qualitative inquiry into patients’ perspectives on individualized priorities for treatment outcomes in inflammatory bowel diseases

Does the single-item self-rated health measure the same thing across different wordings? Construct validity study

Humour and laughing in patients with prolonged incurable cancer: an ethnographic study in a comprehensive cancer centre

Development of algorithms to estimate EQ-5D and derive health utilities from WHOQOL-HIV Bref: a mapping study

Does the EQ-5D-5L benefit from extension with a cognitive domain: Testing a multi-criteria psychometric strategy in trauma patients

The association of socio-economic status, dental anxiety, and behavioral and clinical variables with adolescents’ oral health-related quality of life